XML 50 R23.htm IDEA: XBRL DOCUMENT v3.20.1

Disaggregation of Revenues (Tables)

3 Months Ended

Mar. 31, 2020

Disaggregation of Revenue [Abstract]

Disaggregation of Revenues

The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):

		Three Months Ended March 31, 2020																Three Months Ended March 31, 2019
		U.S.				Europe				Other Locations				Total				U.S.				Europe				Other Locations				Total
Product sales:
Atripla		$	81			$	7			$	7			$	95			$	133			$	16			$	22			$	171
Biktarvy		1,412				181				100				1,693				739				48				6				793
Complera/Eviplera		24				47				5				76				44				62				9				115
Descovy		363				61				34				458				233				68				41				342
Genvoya		612				151				61				824				728				193				94				1,015
Odefsey		269				127				13				409				282				106				9				397
Stribild		34				17				2				53				67				18				11				96
Truvada		383				8				15				406				551				33				22				606
Other HIV(1)		3				2				3				8				11				1				5				17
Revenue share – Symtuza(2)		72				38				2				112				42				24				—				66
AmBisome		18				59				42				119				8				57				28				93
Ledipasvir/Sofosbuvir(3)		53				11				48				112				117				27				81				225
Letairis		83				—				—				83				197				—				—				197
Ranexa		8				—				—				8				155				—				—				155
Sofosbuvir/Velpatasvir(4)		311				122				131				564				230				154				107				491
Vemlidy		73				7				56				136				65				4				32				101
Viread		4				11				25				40				12				14				46				72
Vosevi		33				11				4				48				45				16				2				63
Yescarta		103				37				—				140				90				6				—				96
Zydelig		8				12				—				20				11				15				1				27
Other(5)		42				18				3				63				36				20				6				62
Total product sales		3,989				927				551				5,467				3,796				882				522				5,200
Royalty, contract and other revenues		17				48				16				81				22				56				3				81
Total revenues		$	4,006			$	975			$	567			$	5,548			$	3,818			$	938			$	525			$	5,281

____________________
Notes:
(1)	Includes Emtriva and Tybost
(2)	Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC
(3)	Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC
(4)	Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC
(5)	Includes Cayston, Hepsera and Sovaldi.

X

- References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration